The presenilin-dependent ␥-secretase processing of the ␤-amyloid precursor protein (␤APP) conditions the length of the amyloid ␤ peptides (A␤) that accumulate in the senile plaques of Alzheimer's disease-affected brains. This, together with an additional presenilinmediated -secretase cleavage, generates intracellular ␤APP-derived fragments named amyloid intracellular domains (AICDs) that regulate the transcription of several genes. We establish that presenilins control the transcription of cellular prion protein (PrP c ) by a ␥-secretase inhibitor-sensitive and AICD-mediated process. We demonstrate that AICD-dependent control of PrP c involves the tumor suppressor p53. Thus, p53-deficiency abolishes the AICD-mediated control of PrP c transcription. Furthermore, we show that p53 directly binds to the PrP c promoter and increases its transactivation. Overall, our study unravels a transcriptional regulation of PrP c by the oncogene p53 that is directly driven by presenilin-dependent formation of AICD. Furthermore, it adds support to previous reports linking secretase activities involved in ␤APP metabolism to the physiology of PrP c .
Introduction
Transmissible spongiform encephalopathies (TSE) result from the unconventional conversion of the normal cellular prion protein (PrP c ) into its pathogenic, protease-resistant scrapie isoform PrP s.c. (Aguzzi and Polymenidou, 2004) . The propagation mechanism apparently does not require any nucleic acid as was proposed in the "protein only" theory (Prusiner, 1998) . Tremendous efforts have been devoted to understand the mechanisms by which PrP c converts into PrP s.c. Although the precise process remains to be established, it appears clearly that "prion infection" requires the crucial presence of endogenous PrP c , since PrP c -deficient mice are fully resistant to infection and toxicity after inoculation with pathogenic scrapie-enriched material (Büeler et al., 1993; Brandner et al., 1996) . However, since prion diseases are extremely rare with no more than one case per million of individuals in human beings, it is important to understand the physiological role and regulation of PrP c . PrP c was reported to participate in lymphocyte activation (Cashman et al., 1990) , cellular adhesion processes (Rieger et al., 1997; Gauczynski et al., 2001; Mangé et al., 2002) , neurite growth (Santuccione et al., 2005) , synaptogenesis (Kanaani et al., 2005) , cellular signaling (Mouillet-Richard et al., 2000) , and cell viability (for review, see Linden et al., 2008) . Concerning transcriptional regulation of PrP c , it has been reported that PrP c mRNA levels could be increased either under stress conditions such as ischemia and hypoglycemia, or by some growth factors (Linden et al., 2008) . However, little is known about the molecular pathways underlying these regulatory events. The functional characterization of the human prion promoter (Funke-Kaiser et al., 2001) identified two regulatory regions where sequence analysis revealed consensus sequences for AP-1, Sp1, and Sp2 factors (Mahal et al., 2001; Bellingham et al., 2009) . Our in silico analysis of the human PRioN protein (PRNP) gene promoter also revealed a motif partly matching the binding sequence targeted by the oncogene p53. We have examined the ability of p53 to modulate PrP c promoter transactivation and mRNA expression and we show that p53 acts as a transcriptional activator of PrP c by binding directly to the suspected promoter sequence. Furthermore, we previously established that the ␤-amyloid precursor protein (␤APP-intracellular domain amyloid intracellular domain (AICD) generated after presenilin-dependent ␥-secretasemediated cleavage of ␤APP behaves as a transcriptional activator of p53 (Alves da Costa et al., 2006) . Here, we show that presenilins also control PrP c transcription in a presenilin-dependent manner by increasing AICD-induced p53 expression. Our study is the first demonstration of the involvement of presenilins in the control of PrP c expression and reveals a new pathway linking ␥-secretase and p53 to the direct control of PrP c transcription. Since endogenous PrP c is necessary to allow PrP s.c. infectious process, presenilin-dependent control of PrP c levels could be seen as a means to modulate not only the physiological function of PrP c but also PrP s.c. accumulation. This hypothesis is nicely supported by a recent study showing that a ␥-secretase inhibitor significantly impairs the accumulation of pathogenic prions in vivo (Spilman et al., 2008) , suggesting that such compounds could represent a new class of therapeutic agents against prion diseases.
Materials and Methods
Cell culture and transfections. Embryonic mouse fibroblasts [presenilin-
ArfϪ/Ϫ , and p19 ArfϪ/Ϫ /p53 Ϫ/Ϫ , as well as their respective wild-type controls], ␤APP-over-expressing HEK293 cells and primary cultured neurons were obtained and maintained in culture as previously described (Vincent et al., 1996; Kamijo et al., 1997; Marambaud et al., 1997; Heber et al., 2000; Herreman et al., 2000; Pardossi-Piquard et al. 2005) . Transient transfections in HEK293 cells were performed with Lipofectamine 2000 reagent (Invitrogen), whereas fibroblasts were transiently transfected by means of the mouse embryonic fibroblasts Nucleofector kit (Amaxa Biosystems) as described previously (Sunyach et al., 2007) .
Immunoprecipitation, SDS-PAGE, and Western blotting. N1-containing conditioned media were immunoprecipitated and submitted to 16.5% Tris-tricine gels as previously described (Vincent et al., 2000) . ␤APP, APLP1, APLP2, Fe65, Tip60, and p53 were separated on 8% Trisglycine gels, whereas PrP c , tubulin, PS1, and PS2 were analyzed on 12% Tris-glycine gels. C50 and C59 fragments were separated on 16.5% Tristricine gels. Proteins were then transferred onto Hybond-C nitrocellulose membranes and incubated with the following antibodies: monoclonal SAF32 (N1 and PrP c ; SPIBio), monoclonal anti-␤-tubulin or anti-␤-actin (Sigma), polyclonal anti-NTF-PS1 or anti-Loop-PS2 (Dr. Gopal Thinakaran, University of Chicago, Chicago, IL), polyclonal anti-Fe65 and monoclonal anti-myc (for myc-tagged C50 and C59; Dr. L. Mercken, Vitry-sur-Seine, France), monoclonal anti-HA (HA-tagged Tip60; Covance), polyclonal anti-APLP1 or APLP2 (EMD Biosciences), monoclonal 22C11 (␤APP; Roche Applied Science), or polyclonal anti-p53 (Dr. Jean-Christophe Bourdon, Dundee, Scotland, UK). Blots were revealed by incubations with goat anti-rabbit or goat anti-mouse secondary antibodies coupled to peroxidase (Beckman Coulter) and chemiluminescence recording using a Luminescence Image Analyzer LAS-3000 (Raytest). Quantification of data was performed with the Aida Image Analyzer software (Raytest).
Chronic ␥-secretase inhibitor treatments. Chronic treatment of 4-d-old primary cultured neurons with the ␥-secretase inhibitor DAPT (N-[-(3, 5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butylester; 10 M) was performed by addition of the inhibitor at 0 and 9 h for a total incubation of 24 h then PrP c immunoreactivity was monitored by Western blot as described above.
Semiquantitative and real-time PCR analyses. Total RNA was extracted and purified from mouse embryonic fibroblasts or HEK293 cells with the NucleoSpin RNA II kit (Machery-Nagel). Two micrograms of total RNA were reverse-transcribed using oligo (dT) priming and avian myeloblastosis virus reverse transcriptase (Promega). For semiquantitative PCR, reactions were performed at 94°C for 30 s, then 55°C for 1 min, and finally 68°C for 2 min using 40 cycles, followed by a final extension of 7 min at 68°C. PCR products were analyzed on a 1% agarose gel stained with ethidium bromide. Real-time PCR were performed in an ABI PRISM 5700 sequence detector system (Applied Biosystems) using the SYBR Green detection protocol as outlined by the manufacturer. Specific primers for semiquantitative or real-time PCR were designed using the Primer Express software (Applied Biosystems) and were as follows: mouse PrP c : forward, 5Ј-CTG CTG GCC CTC TTT GTG AC-3Ј and reverse 5Ј-CTT TTT GCA GAG GCC GAC AT-3Ј. Human PrP c : forward, 5Ј-AAT CAA GCA GCA CAC GGT CA-3Ј and reverse 5Ј-TCG GTG AAG TTC TCC CCC TT-3Ј.
Expression levels of human p53 and PrP c genes and mouse PrP c gene were normalized by monitoring RNA levels of human GAPDH and mouse ␥-actin genes using the following primers: forward, 5Ј-TGG GCT ACA CTG AGC ACC AG-3Ј and reverse 5Ј-CAG CGT CAA AGG TGG AGG AG-3Ј for human GAPDH; and forward 5Ј-CAC CAT CGG TTG TTA GTT GCC-3Ј and reverse 5Ј-CAG GTG TCG ATG CAA ACG TT-3Ј for mouse ␥-actin.
Measurements of PrP c promoter transactivation. The 1543 bp of the 5Ј untranslated and promoter region of the human PrP c gene was subcloned into the luciferase reporter vector pGL3basic and used to measure PrP c promoter transactivation as has been extensively described (FunkeKaiser et al., 2001) . Cells grown in 12-well plates were cotransfected with PrP c promoter-luciferase, ␤-galactosidase (to normalize transfection efficiencies), and the indicated cDNAs with Lipofectamine (HEK293 cells) or with the Amaxa Nucleofector kit (mouse embryonic fibroblasts). Thirty-six hours after transfection, luciferase and ␤-galactosidase activities were measured with appropriate enzyme assay systems (Promega).
Site-directed mutagenesis of PrP c promoter. Mutation of the p53 putative binding site located on the human PrP c promoter-luciferase reporter construct (Mahal et al., 2001 ) was introduced using the Quick change site-directed mutagenesis kit (Stratagene) following manufacturer's specifications. The two following sets of primers were purchased from Eurogentec: forward, 5Ј-CCTATTTTCCCCAGGGAGCACCTGGTT-TACGCCC-3Ј; reverse, 5Ј-GGGCGTAAACCA-GGTGCTCCCTGGG-GAAAATAGG-3Ј. The resulting construct (CATG replaced by AGCA) was verified by sequencing.
Chromatin immunoprecipitation assay. Chromatin immunoprecipitation assay (ChIP) was performed according to the instructions of the Chip-IT kit (Active Motif). Briefly, to prepare chromatin, HEK293 cells were seeded in three 150 mm dishes and allowed to reach 70 -80% confluency. Cells were fixed, recovered in PBS, cross linked, and processed for chromatin preparation. DNA obtained was digested with the shearing enzyme provided in the kit as recommended by the supplier, yielding chromatin fragments of 200 -500 bp in size. Each immunoprecipitation was performed on 50 g of chromatin in the ChIP immunoprecipitation buffer supplied, with 5 g of anti-p53 primary antibody (Active Motif) or irrelevant antibody (IgG and RNApol IgG) as negative controls. Immune complexes were collected with 40 l of a solution of protein G-Sepharose. After elution, cross links were reversed and RNA digested using RNase (100 g/ml). To digest proteins, SDS (1%), and proteinase K (100 g/ml) were added, and the samples were incubated overnight at 37°C. The beads were washed as recommended and DNA was purified on columns provided. PCR amplification was performed using primers specific for the Ϫ326/Ϫ150 bp region of the PrP c promoter (forward, 5Ј-CAGGAGCCACACAGTTGAAACAGA-3Ј; reverse, 5-AGGGTGATT-TACGTAAAATAGCAAA-3Ј).
Transgenic mouse brain tissue preparation. Pieces of brains from APP Ϫ/Ϫ and APP Ϫ/Ϫ /APLP2 Ϫ/Ϫ mice (Heber et al., 2000) , and Fe65 transgenic and Fe65/AICD transgenic mice (Ryan and Pimplikar, 2005) , together with their respective wild-type controls, were homogenized in lysis buffer (10 mM Tris/HCl, pH 7.5, containing 150 mM NaCl, 0.5% Triton X-100, 0.5% deoxycholate, 5 mM EDTA). Protein expressions were analyzed by Western blot as described above.
Immunofluorescence analysis.
Ϫ/Ϫ fibroblasts were grown on glass coverslips in 35 mm dishes. At 50% of confluence, cells were fixed with 1.5% paraformaldehyde for 20 min at room temperature and washed three times with PBS. Permeabilization was performed by the addition of 0.1% Triton X-100 for 5 min followed by three PBS washes (nonpermeabilized cells were maintained in PBS during this time). After incubation for 1 h with 1% nonfat milk in PBS (to limit nonspecific fixation of antibodies), cells were incubated overnight at 4°C with the indicated primary antibodies in 1% nonfat milk/PBS). After three washes with PBS, cells were incubated for 1 h with adequate secondary antibodies conjugated to Alexa Fluor-594 and Alexa Fluor-488 respectively (Interchim). Coverslips were washed, incubated with DAPI to counterstain the nuclei and mounted in Vectashield-mounting medium (Vector Laboratories). Staining was visualized as previously described (Sunyach et al., 2007) .
Statistical analysis. Statistical analyses were performed with the PRISM software (GraphPad) by using the unpaired t test for pairwise comparisons.
Results

Presenilins modulate cellular prion protein at a transcriptional level
We examined the influence of presenilins on the expression of PrP c . Figure 1 A shows that PrP c immunoreactivity was drastically decreased (50 Ϯ 3.7% inhibition compared with wild-type cells, n ϭ 20, p Ͻ 0.0001) in homogenates prepared from presenilins 1-and 2-deficient (PS Ϫ/Ϫ ) mouse fibroblasts. As expected, the secretion of the N-terminal metabolite of PrP c referred to as N1 (Chen et al., 1995; Vincent et al., 2000 Vincent et al., , 2001 was concomitantly reduced by PS deficiency (Fig. 1 A) . In situ staining of PrP c on nonpermeabilized intact cells revealed a drastic decrease in cell surface-associated immunofluorescence in PS-deficient fibroblasts ( Fig. 1 B, left panels). PrP c labeling on Triton X-100 permeabilized cells revealed a similar decrease of PrP c expression triggered by PS depletion (Fig. 1 B, right panels) , indicating that the reduction of membraneassociated PrP c expression was not caused by an intracellular accumulation of the protein that would have been triggered by a defect in PS-dependent trafficking of PrP c to the plasma membrane.
We assessed whether the observed reduction in PrP c immunoreactivity resulted from a decrease in its mRNA transcription. We took advantage of the design of a PrP c promoter construct that harbors 1543 bp of the 5Ј-untranslated promoter region of the PrP c human gene in-frame with a luciferase reporter gene (Funke-Kaiser et al., 2001) to establish that PrP c promoter transactivation was drastically reduced in PS-deficient fibroblasts (63 Ϯ 2.5% of reduction compared with wild-type cells, n ϭ 15, p Ͻ 0.0001) (Fig. 2C ). This was accompanied by a lowering of PrP c mRNA levels measured by both semiquantitative RT-PCR (Fig. 2 A) and real-time PCR analyses (46.6 Ϯ 8.4% of reduction, n ϭ 9, p Ͻ 0.0001) (Fig. 2 D) in PS-deficient fibroblasts. Importantly, we were able to substantially rescue PrP c promoter transactivation (1.88 Ϯ 0.13-fold increase, p Ͻ 0.0001) (Fig. 2C ) and mRNA levels (1.69 Ϯ 0.14-fold increase, p Ͻ 0.05) (Fig. 2 D) after transient overexpression of both PS1 and PS2 in PS-deficient cells ( Fig. 2 B) . Overall, the above data demonstrate that the PSs control PrP c expression at the transcriptional level.
␤APP and APLPs are involved in the regulation of PrP c transcription PSs are pleiotropic proteins (Checler, 1999) that are thought to harbor an aspartyl protease activity referred to as ␥-secretase (Wolfe et al., 1999) . To assess whether the PS-dependent control of PrP c expression could be linked to ␥-secretase activity, primary cultured neurons were exposed to DAPT, a specific PSdirected inhibitor (Dovey et al., 2001 ). Figure 3A clearly shows that chronic treatment of neurons with DAPT significantly reduced PrP c expression (37 Ϯ 4% inhibition, n ϭ 3, p Ͻ 0.0001). The ␤APP is historically the first protein described as a substrate of the PS-dependent ␥-secretase activity (De Strooper et al., 1998) . Furthermore, PS-dependent cleavage of ␤APP yields a C-terminal metabolite called AICD that has been suggested to behave as a transcription factor (Müller et al., 2008) . We therefore examined whether ␤APP could be involved in the control of PrP c expression and promoter transactivation. We first showed that ␤APP overexpression triggers a significant increase of PrP c immunoreactivity (1.6 Ϯ 0.07-fold increase, n ϭ 8, p Ͻ 0.0001) (Fig. 3B ) in human stably transfected HEK293. To rule out any artifactual effect resulting from overexpression procedure and to confirm that endogenous ␤APP indeed controls PrP c expression, we monitored PrP c immunoreactivities in ␤APP-deficient fibroblasts, and we observed a reduction of PrP c expression in absence of ␤APP (19.3 Ϯ 3.6% inhibition, p Ͻ 0.0001) (Fig. 3C) , a phenotype reminiscent of that observed in presenilin-deficient cells (Fig. 1 A) . Interestingly, the lowering of PrP c expression was further amplified in ␤APP Ϫ/Ϫ /APLP2 Ϫ/Ϫ fibroblasts (63 Ϯ 6% inhibition, p Ͻ 0.0001) (Fig. 3C ) that are lacking APLP2, a member of the ␤APP family that also undergoes PS-dependent ␥-secretase-like cleavages (Scheinfeld et al., 2002) . Interestingly, we show that PrP c immunoreactivity was fully restored by transient transfections of ␤APP or APLP2 cDNAs in ␤APP Ϫ/Ϫ / APLP2 Ϫ/Ϫ cells (Fig. 3D ). It should be noted that APLP1, another member of the ␤APP family that is expressed in the brain but absent in fibroblasts, mimics the potential of rescue harbored by ␤APP and APLP2 (Fig. 3D) . The above findings were further supported by in vivo data showing a dramatic reduction of PrP c expression in both ␤APP-and ␤APP/APLP2-deficient mouse brains (Fig. 3E) . Finally, immunofluorescence staining of PrP c at the cell surface of permeabilized and nonpermeabilized ␤APP
Ϫ/Ϫ cells indicated that the combined absence of ␤APP and APLP2 drastically impaired PrP c expression at the plasma membrane (Fig. 4 A) , as was observed in PS-deficient cells.
Four lines of data indicate that ␤APP and APLP2 control PrP c expression at a transcriptional level. First, the transactivation of the human PrP c promoter was significantly impaired by ␤APP and ␤APP/APLP2 depletion (63 Ϯ 5% reduction, p Ͻ 0.0001 and 81 Ϯ 3% decrease, p Ͻ 0.0001, respectively) (Fig. 4 B) . Second, ␤APP and ␤APP/APLP2 deficiency lowered PrP c mRNA levels as shown by semiquantitative (Fig. 4C) and quantitative real-time PCR (70 Ϯ 14% decrease, p Ͻ 0.01 and 69 Ϯ 10% inhibition, p Ͻ 0.003, respectively) (Fig. 4 D) . Third, ␤APP partially restored both PrP c promoter transactivation (2.07 Ϯ 0.05-fold increase, p Ͻ 0.0001) and PrP c mRNA levels (3.02 Ϯ 0.37-fold increase, p Ͻ 0.03) (Fig. 4 E) . Fourth, both luciferase activity (2.75 Ϯ 0.14-fold increase, n ϭ 6, p Ͻ 0.0001) and PrP c mRNA levels (1.93 Ϯ 0.11-fold increase, n ϭ 10, p Ͻ 0.0001) were significantly augmented after ␤APP overexpression in HEK293 cells, ruling out a possible cell specific ␤APP-mediated control of PrP c transcription (data not shown). The ␥-secretase-derived ␤APP metabolite AICD controls PrP c expression and promoter transactivation The ␤APP-related effects on PrP c expression and transcription were fully reminiscent of those associated with PSs. Since the latter appeared dependent on ␥-secretase activity, we reasoned that the production of a ␤APP metabolite generated by PS-dependent ␥-secretase activity could account for the observed modulation of PrP c mRNA levels and protein expression. Interestingly, AICD59 (C59) and AICD50 (C50) derive from the ␥-and -secretase attacks of ␤APP, respectively, and have been suggested to modulate a series of genes at a transcriptional level (Müller et al., 2008) . Therefore, we examined the possibility that AICD could modulate the transcription of PrP c . The adaptor protein Fe65 and the histone acetyltransferase Tip60 have been reported to enhance AICD immunoreactivity and to promote AICD translocation to the nucleus (Cao and Südhof, 2001 ). Therefore, we transiently transfected C50 or C59 together with Fe65 and Tip60 in ␤APP Ϫ/Ϫ
/APLP2
Ϫ/Ϫ fibroblasts (Fig. 5A) . Clearly, both C50 and C59 overexpression significantly enhanced PrP c immunoreactivity (1.14 Ϯ 0.05-fold increase, p Ͻ 0.005 and 1.55 Ϯ 0.16-fold increase, p Ͻ 0.005, respectively) (Fig. 5A) , PrP c promoter transactivation (1.13 Ϯ 0.04-fold increase, p Ͻ 0.002 and 1.64 Ϯ 0.12-fold increase, p Ͻ 0.0001, respectively) (Fig. 5B) , and PrP c mRNA levels (2.47 Ϯ 0.12-fold increase, p Ͻ 0.05 and 1.73 Ϯ 0.04-fold increase, p Ͻ 0.05, respectively) (Fig. 5C ). Here again, both C50 and C59 heighten PrP c mRNA levels (2.41 Ϯ 0.26-fold increase, p Ͻ 0.01 and 1.68 Ϯ 0.19-fold increase, p Ͻ 0.03, respectively) in HEK293 cells (Fig. 5D) . Finally, we took advantage of transgenic mice overexpressing both C59 and Fe65 (Ryan and Pimplikar, 2005) to determine whether the AICD-mediated control of PrP c expression described here also takes place in vivo in mouse brain. Indeed, C59/Fe65 transgenic mice show enhanced cerebral expression of PrP c compared with Fe65 single transgenic animals (Fig. 5E ). Since PS-dependent ␥-secretase activity is able to cleave other substrates than ␤APP, thereby generating other ICDs, we examined the effect of notch ICD (NICD), m⌬ENotch (which engenders NICD after ␥-secretase cleavage), or the ␥-secretase-derived C-terminal products of E-and N-cadherins (E-Cad/CTF2 and N-Cad/CTF2, respectively), and established that none of these fragments were able to modulate PrP c levels (data not shown).
AICD-mediated regulation of PrP
c is p53-dependent and occurs through direct binding of p53 to PrP c promoter The question arises by which mechanisms AICD could control PrP c promoter transactivation, and thereby, mRNA and protein levels. We have previously demonstrated that AICDs can positively control p53 at the transcriptional level (Alves da Costa et al., 2006) . In silico examination of the PrP c promoter revealed a putative although incomplete p53-binding site (el-Deiry et al., 1992) (Fig. 6 B) . It was therefore tempting to speculate on the possibility that p53 could account for the AICD-mediated regulation of PrP c transcription. Six lines of independent data confirm that this was indeed the case. First, PrPc mRNA levels were reduced by p53 depletion (Fig. 6 A) . Second, C50-and C59-mediated effects on PrP c mRNA levels were fully p53-dependent because the C50/59-induced increase in PrP c mRNA was prevented by p53 depletion (Fig. 6 A) . Third, PrP c expression (de- Ϫ/Ϫ fibroblasts were transiently transfected with either empty pcDNA3 vector (CT) or ␤APP cDNA. Thirty-six hours after transfection, ␤APP immunoreactivity (left), PrP c promoter transactivation (middle), and mRNA levels (right) were measured as described in Materials and Methods. Bars express percentage of control promoter transactivation or mRNA levels recovered in WT cells and represent the means Ϯ SEM of 8 or 3 independent experiments, respectively. *p Ͻ 0.03; ****p Ͻ 0.0001.
crease of 34 Ϯ 8%, n ϭ 5, p Ͻ 0.01) (Fig. 6C) , promoter transactivation (decrease of 49 Ϯ 5%, p Ͻ 0.001) (Fig. 6 D) , and mRNA levels (decrease of 55 Ϯ 15%, p Ͻ 0.01) (Fig. 6 E) were reduced by p53 depletion. Fourth, p53 cDNA transfection in p53-deficient cells rescued PrP c promoter activation (2.44 Ϯ 0.07-fold increase, p Ͻ 0.0001) (Fig. 6 D) and mRNA levels (2.6 Ϯ 0.13-fold increase, p Ͻ 0.001) (Fig. 6 E) . Fifth, ChIP, using a set of primers framing the putative p53 binding site described above, showed that p53 physically bound to the human PrP c promoter (Fig. 6 F,  lane 5) . Sixth, mutation of the putative p53 binding site located on the PrP c promoter reporter construct not only resulted in a significant decrease of baseline luciferase activity in p19
Arf Ϫ/Ϫ cells expressing endogenous p53 levels (Fig. 6G , compare WT and Mut), but also abolished the ability of overexpressed p53 to trigger PrP c promoter transactivation (Fig. 6G , compare WT/p53 and Mut/p53). This set of data brings the demonstration that p53 could act as a direct activator of PrP c promoter transactivation and strongly argues in favor of a p53-mediated AICD-dependent regulation of PrP c transcription.
Discussion
Although the role of the PrP c in transmissible spongiform encephalopathies has been clearly established (Aguzzi and Polymenidou, 2004) , its physiological function as well as the regulation of its expression are yet poorly understood. The demonstration that PrP c -deficient mice are viable with no obvious deleterious phenotype (Büeler et al., 1992) would suggest either that endogenous PrP c does not fulfill any vital functions, or that such functions could be complemented by yet unknown proteins/mechanisms. Nevertheless, several studies indicated that PrP c could contribute to several distinct processes, including lymphocyte activation, synaptic transmission, cell adhesion, signaling, and apoptosis (for review, see Linden et al., 2008) . Other works also suggested that PrP c could be involved in the neuronal differentiation of PC12 cells triggered by either interleukin-6 or nerve growth factor, as shown by increased expression of PrP c mRNA levels (Lazarini et al., 1994) . Consistent with a pivotal link between NGF and PrP c , PrP c mRNA expression was also increased after intracerebral injection of this growth factor in cholinergic neurons (Mobley et al., 1988) . Accordingly, Satoh et al. (1998) reported on cell-specific modulation of PrP c mRNA levels after treatment with other cytokines (interleukin 1␤), growth factors (tumor necrosis ␣), and tumor promoting drugs (phorbol esters).
Molecular cloning of the human PRNP gene promoter facilitated the understanding of the transcriptional regulation of PrP c (Funke-Kaiser et al., 2001; Mahal et al., 2001) . Thus, the 5Ј-flanking region of PRNP revealed several putative binding sites for transcription factors including Sp1, AP1, AP2, c-REL, and Nkx2-5, suggesting stimulus-dependent and cellspecific mechanisms of transcriptional regulation. Interestingly, Mahal et al. (2001) also reported a CATG sequence located 746 nt upstream to the transcriptional start site of the human PRNP gene. This CATG motif partially mimics the p53 consensus binding site sequence (el-Deiry et al., 1992) . Whether this putative p53-binding domain was functional remained to be established. Nevertheless, the concomitant presence of p53 and SP-1 binding sequences on the PRNP promoter was interesting with respect to the fact that these two transcriptional factors were reported to physically interact to form functional hetero-complexes (Borellini and Glazer, 1993; MacLeod, 1993; Gualberto and Baldwin, 1995) .
Our study clearly demonstrates that p53 acts as a functional activator of the PRNP gene promoter transcription. First, p53 deficiency drastically lowers PrP c expression, mRNA levels, and promoter transactivation that all could be rescued by transient transfection of p53 cDNA. Second, substitution of the putative p53-binding site CATG by AGCA fully abolishes p53-dependent upregulation of PrP c transcription. Third, ChIP unravels a direct interaction between p53 and PrP c promoter. Therefore, our study establishes a physical and functional link between p53 and PRNP promoter triggering transcriptional activation and increased expression of PrP c . Noteworthy, a very recent study described an ATM (ataxia-telangectasia-mutated)-mediated binding of p53 to the PRNP promoter in response to copperinduced oxidative stress that promotes an elevation of PrP c (Qin et al., 2009 ).
It should be noted, however, that the PRNP gene did not emerge when a global mapping of p53-binding sites in the human genome was performed recently by ChIP coupled to paired-end ditag sequencing (PET) (Wei et al., 2006 PS-dependent ␥-secretase targets a series of substrates (Wakabayashi and De Strooper, 2008) that could have been theoretically considered as putative mediators of p53-dependent PS-associated modulation of PrP c . We examined the possibility that PS/␥-secretase-mediated cleavages of ␤APP and APLP could be responsible for this phenotype, because we previously established that AICD and ALID (␤APP-like intracellular domain), the intracellular metabolites of the ␤APP and APLP, respectively, generated by PS-dependent ␥-secretase activity, could control p53 levels (Alves da Costa et al., 2006) . Five lines of data indicate that this was indeed the case: first, ␤APP overexpression increases PrP c expression; second, ␤APP and APLP depletion lowered PrP c immunoreactivity, promoter transactivation. and mRNA levels in fibroblasts as well as in mice brains; third, ␤APP and APLP cDNA transfection could rescue PrP c promoter transactivation and mRNA levels in ␤APP/ APLP2 deficient cells; fourth, AICD increases PrP c expression, promoter transactivation, and mRNA levels after overexpression in both ␤APP/APLP2-deficient fibroblasts, whereas AICDtransgenic mice display higher PrP c levels than wild-type animals; and fifth, AICD-mediated modulation of PrP c mRNA levels was fully abolished by p53 deficiency. Overall, our study demonstrates for the first time that PSs control PrP c levels via its ability to generate AICD. Thereafter, AICD increases p53 that ultimately acts as a transcriptional activator of PRNP gene promoter (Fig. 7) . Moreover, it appears that AICDmediated cascade leading to the modulation PrP c is rather specific since other ␥-secretase-derived fragments such as . The cleavage of ␤APP by the ␤-secretase BACE1 yields the C99 fragment that undergoes subsequent attack by the presenilin-dependent ␥-secretase. This results in the concomitant productions of A␤ and AICD. AICD associates with the adaptor protein Fe65 and the histone acetyltransferase Tip60 to form a stable complex that translocates into the nucleus where it can induce the promoter transactivation of several gene targets including p53 (Alves da Costa et al., 2006 ) that acts as a direct activator of PrP c promoter transactivation directly (this study). Therefore, PS-dependent ␥-secretase-mediated production of AICD ultimately leads to a p53-dependent augmentation of cellular prion protein expression at the plasma membrane.
